Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Long-Term Investments (2016 - 2017)

AC Immune has reported Long-Term Investments over the past 3 years, most recently at $127711.0 for Q4 2017.

  • Quarterly Long-Term Investments rose 48.5% to $127711.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $127711.0 through Dec 2017, up 48.5% year-over-year, with the annual reading at $127711.0 for FY2017, 48.5% up from the prior year.
  • Long-Term Investments was $127711.0 for Q4 2017 at AC Immune, up from $125491.4 in the prior quarter.
  • Over five years, Long-Term Investments peaked at $127711.0 in Q4 2017 and troughed at $85895.2 in Q4 2015.
  • The 3-year median for Long-Term Investments is $87135.3 (2016), against an average of $102447.0.
  • Year-over-year, Long-Term Investments increased 0.12% in 2016 and then skyrocketed 48.5% in 2017.
  • A 3-year view of Long-Term Investments shows it stood at $85895.2 in 2015, then increased by 0.12% to $86002.1 in 2016, then skyrocketed by 48.5% to $127711.0 in 2017.
  • Per Business Quant, the three most recent readings for ACIU's Long-Term Investments are $127711.0 (Q4 2017), $125491.4 (Q1 2017), and $86002.1 (Q4 2016).